Welcome to our dedicated page for DataMeds AI SEC filings (Ticker: MEDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DataMeds AI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DataMeds AI's regulatory disclosures and financial reporting.
DataMeds AI, Inc. (MEDS) reports that holders of 50.2% of its common stock, representing a majority of the 3,197,633 shares outstanding as of August 18, 2026, have approved by written consent several corporate actions without a meeting or proxy solicitation.
The approvals include a “blank check” preferred stock amendment authorizing up to 1,000,000 preferred shares and the prompt designation of 25,000 shares as Series A Convertible Preferred Stock tied to the May 2026 financing. That financing involved $21.13 million principal of 0% May 2026 Notes and warrants, potentially convertible into common stock at variable prices with floors as low as $1.00 per share.
DataMeds provides dilution tables showing that, depending on conversion prices, combined conversions of the May 2026 Notes or Series A Preferred Stock and exercises of related PIPE and placement agent warrants could result in dilution of existing common stockholders up to the 90%+ range. The Series A Preferred Stock carries a 10% annual dividend added to stated value, voting rights, and priority in liquidation, and the company notes potential anti-takeover effects from the blank check preferred authorization. Stockholders also approved the reelection of five directors to serve until the 2027 annual meeting, Nasdaq Listing Rule 5635(d) approval for prior and potential issuances to Silverback Capital Corporation, and ratification of Suri & Co. as independent auditor for 2026.
DataMeds AI, Inc. reported second quarter 2026 net revenues of $1.78 million, down sharply from $7.79 million a year earlier, but up 14% sequentially from the first quarter, exceeding internal projections. Gross profit was $0.18 million, and the company recorded an operating loss of $7.35 million.
After $11.02 million in net other expense, including an $8.88 million loss on extinguishment of debt, net loss for the quarter was $18.36 million, or $7.13 per share. Total assets were $32.76 million against liabilities of $52.26 million, resulting in a stockholders’ deficit of $19.50 million.
The company highlighted a pending Datavault Transaction, a planned September 2026 launch of the Health Lives Here app with NFL Alumni Health targeting GLP‑1 users, a $6.5 million capital raise, restructuring of $14.5 million in debt toward a preferred equity swap, a 1-for-50 reverse stock split, and new lock-up agreements covering about 49% of outstanding shares.
DataMeds AI, Inc. reported sharply weaker results for the three and six months ended June 30, 2026. Net revenues fell to $1.78 million from $7.79 million in the quarter and to $3.34 million from $18.65 million year to date, driven largely by a steep decline in distribution services revenue caused by liquidity constraints that limited product procurement and fulfillment. Gross profit was only $182,204 for the quarter, while operating expenses of $7.53 million produced a loss from operations of $7.35 million.
After heavy non‑operating charges, including $8.88 million loss on extinguishment of debt and a $0.77 million contract termination fee, total other expense reached $11.0 million, resulting in a net loss of $18.36 million for the quarter and $26.11 million year to date. The company ended June 30, 2026 with cash of $2.46 million, total assets of $32.76 million, total debt of $31.81 million, and a stockholders’ deficit of $19.50 million. Management obtained $14.2 million of new convertible note financing, completed a 1‑for‑50 reverse stock split and regained Nasdaq’s $1.00 bid compliance, but still faces an equity deficiency notice and a Nasdaq deadline of October 12, 2026 to restore stockholders’ equity to at least $2.5 million. The company disclosed that these conditions raise substantial doubt about its ability to continue as a going concern within twelve months.
DataMEDS AI, Inc. reports that Datavault AI Inc. plans a voluntary one-time distribution of Dream Bowl Meme Coin digital tokens to holders of DataMEDS common stock. Record holders as of the close of business on August 7, 2026 are eligible, with Datavault’s board retaining the right to move this date later.
Each eligible share of DataMEDS common stock corresponds to 50 Dream Bowl Meme Coins, to be delivered beginning on September 9, 2026, subject to Datavault’s board being able to change that date or revoke the distribution entirely. To receive tokens, holders must open a Datavault digital wallet and execute an Opt-In Agreement via the distribution website. Datavault states a fair market value of $0.01 per Meme Coin as of August 7, 2026, notes that the tokens are intended as non-investment digital collectibles, and highlights extensive risk factors around volatility, regulatory uncertainty, security, liquidity and tax treatment, including that the distribution may be treated as an in-kind dividend for tax purposes.
DataMEDS AI, Inc. filed a Notification of Late Filing indicating it will not submit its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 by the original due date of August 14, 2026. The company states the report cannot be completed on time without unreasonable effort or expense and that it needs additional time to finalize the preparation and review of its financial statements and related disclosures. DataMEDS AI, Inc. expects to file the Form 10-Q within the five-calendar-day extension period permitted under Rule 12b-25 of the Securities Exchange Act of 1934.